CareCost Vials
1 × 920 mg
1 billing unit = 1 mg
920 mg dose → 920 billing units
J2351 · ocrelizumab and hyaluronidase-ocsq
920 mg/23,000 units single-dose vial · JZ on every claim
Calculate this patient's units ↓920 mg subcutaneously into the abdomen over about 10 minutes, once every 6 months · the same dose for every labeled indication
Your Ocrevus Zunovo dose and 920 billing units carry straight into the estimate.
Pick the payer, enter what the patient has already met toward the deductible and the out-of-pocket maximum, and choose a copay program. CareCost returns the patient's share as a good faith estimate you can hand over.
Patient owes, 920 mg
Change the payer and the estimate re-prices against that payer's own published rate. The result is a good faith estimate for the patient.
36 payer price files · Commercial + Medicare · Copay and foundation status · Deductible, coinsurance and out-of-pocket math
Ocrevus Zunovo J2351 is billed in units of 1 mg: ordered dose ÷ 1 mg = billing units. The labeled dose is a flat 920 mg for every indication, so the calculation has no per-kilogram multiplication and nothing to round -- 920 mg ÷ 1 mg = 920 billing units, every time.
Ocrevus Zunovo ships as a 920 mg/23,000-unit single-dose vial in 23 mL, sized to match the labeled dose exactly, so the amount drawn (920 mg) equals the amount administered (920 mg) with nothing left over. That is why JZ (no drug discarded) is the modifier on every Ocrevus Zunovo claim -- unlike a multi-dose-vial drug, there is no per-vial waste math to do.
Medicare pays $48.06 per mg (ASP+6%), effective for claims in Q3 2026 — $44,215.20
for the 920-unit dose above.
| Product | HCPCS | Dose | Billing units |
|---|---|---|---|
| Ocrevus Zunovo (subcutaneous) | J2351 | 920 mg | 920 |
| Ocrevus (IV, maintenance dose) | J2350 | 600 mg | 600 |
| Ocrevus (IV, each initial infusion) | J2350 | 300 mg | 300 |
| Briumvi (IV, ublituximab-xiiy) | J2329 | 450 mg | 450 |
Ocrevus IV's initial dose splits into two 300 mg infusions 14 days apart, each billed as 300 units -- see the claim-count comparison below. Briumvi is a different molecule (ublituximab-xiiy, TG Therapeutics), shown here for its unit basis, not as a clinical recommendation.
JZ — no discarded drug from the single-dose vial. JW — discarded drug, reported on its own claim line. One of the two is required on every J2351 claim per CMS's July 1, 2023 single-dose container policy.
J2351 × 920 JZ · 96401 × 1 (or 96372, per the payer's position). This is the
case on every Ocrevus Zunovo claim, because the single-dose vial is sized to match the labeled dose exactly.
There is no ordinary JW scenario for this product: the 920 mg dose and the 920 mg vial are the same number. If a payer disputes a partial administration, document the discarded amount in the chart and bill it on its own JW line, same date of service, same HCPCS code -- but that is not a routine claim shape here.
Genentech's own billing guidance defaults to 96401 (chemotherapy administration,
subcutaneous or intramuscular, non-hormonal anti-neoplastic), which pays $71.81. Some payers instead require
96372 (therapeutic, prophylactic or diagnostic injection, subcutaneous or intramuscular), which
pays $15.36, for the same ten-minute administration -- a 4.7x spread. 96413 and 96365
(IV infusion administration) never apply to J2351; those codes belong to the infused product, J2350.
What to do: default to 96401, since that is the code Genentech's guidance leads with and the code this reference's manifest uses. Before the first claim for a new payer, confirm their position -- bill 96372 instead if that payer's policy or past remittance says so, and keep a per-payer note so the second claim does not repeat a denial the first one already resolved.
96401 and 96372 are both subcutaneous/intramuscular injection codes -- there is no infusion time, initial hour, or additional hour to report for either one, because Ocrevus Zunovo is not infused. The visit itself typically runs about 10 minutes, including the injection.
Infused Ocrevus splits its first dose into two 300 mg infusions 14 days apart, each its own claim, followed by a 600 mg maintenance infusion later in the year -- three J2350 claims in a new patient's first year. Zunovo has no loading split: the first 920 mg injection is identical to every one after it, so a new Zunovo patient's first year carries two J2351 claims.
Fewer claims does not mean a smaller bill: Zunovo's 1,840 units at $48.06/mg allow more than the infusion's 1,200 units at $60.97/mg, over the same first year. See the pricing comparison on the reference page for the full-year totals.
Ocrevus Zunovo is supplied as a 920 mg ocrelizumab / 23,000 unit hyaluronidase-ocsq single-dose vial in 23 mL — there is no other size. NDC 50242-554-01 (10-digit) / 50242-0554-01 (11-digit), Genentech. See the FDA prescribing information for full dosing and administration instructions.
J2351 is the subcutaneous ocrelizumab code. The infused form of the same molecule bills under a separate code, J2350, at a different labeled dose (600 mg maintenance) and a different administration code (96413 or 96365). Briumvi (ublituximab-xiiy, TG Therapeutics), a different anti-CD20 molecule sometimes compared against this class, bills under J2329. See the HCPCS hub for coding across the family. The Medicare rate for every quarter is on the cost page →
920 billing units. Ocrevus Zunovo J2351 bills 1 unit per 1 mg, so a 920 mg dose is always 920 units.
J2351. The infused version of the same molecule, Ocrevus, bills under a different code, J2350, at a different dose — 600 mg instead of 920 mg — so the two are never interchangeable on a claim.
JZ on every claim. The 920 mg dose exactly fills the single-dose 920 mg vial, so nothing is left over to discard — there is no ordinary JW scenario for this product.
Both are in use. Genentech's own billing guidance defaults to 96401 ($71.81); some payers require 96372 ($15.36) instead for the same ten-minute injection. Confirm the payer's position before the first claim and keep a per-payer note so the second claim does not repeat a denial the first one already resolved.
Two claims for Zunovo against three for infused Ocrevus. The infusion splits its first dose into two 300 mg infusions 14 days apart, then a 600 mg maintenance infusion — three claims in year one. Zunovo has no loading split: the first 920 mg injection is identical to every one after it, so year one carries two claims.
$48.06 per mg (ASP+6%), effective for claims in Q3 2026 — $44,215.20 for the standard 920 mg dose.
Data current: pricing Q3 2026 · payer policies Aug 2026
Sources: CMS ASP pricing files (Q3 2026); Medicare physician fee schedule (96401 and 96372, national non-facility); FDA-approved prescribing information (Ocrevus Zunovo label, Genentech, BLA 761371); CMS single-dose container JW/JZ policy (effective July 1, 2023); CPT codebook administration-code guidance; the CareCost Clearance coverage corpus (27 payers, 251 ocrelizumab rules).
Reviewed September 13, 2026 by Erin Rose, CareCost Estimate founder. Methodology →